SCHEDULE 13G/A: BlackRock Amends SEC Filing, Disclosing 8.4% Stake in Novavax Inc.
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.4% of Novavax Inc.'s common stock as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 13,450,411 shares of Novavax Inc. common stock.
- This stake represents 8.4% of Novavax Inc.'s total outstanding common stock.
- BlackRock holds sole voting power over 13,259,500 shares and sole dispositive power over 13,450,411 shares.
- The filing is an Amendment No. 5 to a Schedule 13G, indicating an update to previously reported ownership.
- BlackRock, Inc. is classified as a parent holding company (HC) for the purpose of this filing.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Novavax Inc.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities that may beneficially own shares, with some potentially holding 5% or more individually.
Sentiment
Score: 5
Explanation: Neutral. A Schedule 13G filing is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the issuer's performance or outlook. It's a routine regulatory update.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Novavax Inc.'s future performance or BlackRock's investment strategy beyond the passive nature of the holding.
Management Comments
- BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing is a routine disclosure by a major institutional asset manager, BlackRock, Inc., regarding its passive investment stake in a biotechnology company, Novavax Inc. Such disclosures are common in the financial industry to ensure transparency of significant ownership positions.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holding in Novavax Inc., which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney that was revoked by the new one. |
| 2024-12-31 | Date of the event which required the filing of this statement (reporting period end date). |
| 2025-01-21 | Date of the new Power of Attorney executed by BlackRock, Inc. |
| 2025-02-05 | Date of filing of this Schedule 13G Amendment No. 5. |
Keywords
Novavax Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, NVAX, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.